Amneal Pharmaceuticals, INC Form 4 insider transactions

Amneal Pharmaceuticals Executive Vice President Nikita Shah sold 50,000 shares of Class A Common Stock on August 12, 2025, under a pre-arranged trading plan.

Amneal Pharmaceuticals' EVP and Chief Legal Officer, Jason B. Daly, sold 22,000 shares of Class A Common Stock for approximately $199,100.

Amneal Pharmaceuticals' Executive Vice President, Andrew S. Boyer, sold 33,436 shares of Class A Common Stock for approximately $302,600.

Amneal Pharmaceuticals, Inc. Director Gautam Patel sold 94,906 shares of Class A Common Stock for approximately $8.02 per share on June 16, 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

Amneal Pharmaceuticals Director Gautam Patel sold 56,426 shares of Class A Common Stock on June 10, 2025, for a weighted average price of $8.02 per share.

Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, sold 49,140 shares of Class A Common Stock at an average price of $7.58 on May 16, 2025.

Director John Kiely of Amneal Pharmaceuticals sold 50,000 shares of Class A Common Stock at an average price of $7.59 on May 12, 2025.

Director Buchi J Kevin reports acquisition and disposal of Amneal Pharmaceuticals Class A Common Stock and Restricted Stock Units.

Director Shlomo Yanai reports acquisition of Amneal Pharmaceuticals Class A Common Stock through vesting of restricted stock units.

Director Deborah M. Autor reports acquisition and disposal of Amneal Pharmaceuticals Class A Common Stock units.

Director Ted C. Nark reports acquisition and disposal of Amneal Pharmaceuticals Class A Common Stock and Restricted Stock Units.

Director John Kiely reports acquisition of Amneal Pharmaceuticals Class A Common Stock through vesting of restricted stock units.

Director Jeffrey P. George acquired 40,258 shares of Amneal Pharmaceuticals Class A Common Stock through the vesting of restricted stock units on May 5, 2025.

Director Alva Emily Peterson reports the acquisition of 40,258 shares of Amneal Pharmaceuticals Class A Common Stock on May 5, 2025, through the vesting of restricted stock units.

Director Paul M. Meister reports acquisition and disposal of Amneal Pharmaceuticals Class A Common Stock units.

Gautam Patel, a director at Amneal Pharmaceuticals, exercised stock options and acquired restricted stock units, increasing his beneficial ownership of Class A Common Stock.

Director Gautam Patel of Amneal Pharmaceuticals sold a total of 8,668 shares of Class A Common Stock on May 2nd and 5th, 2025, under a pre-arranged 10b5-1 trading plan.

Director Gautam Patel of Amneal Pharmaceuticals sold 80,000 shares of Class A Common Stock at an average price of $8.3 on April 1, 2025, according to a Form 4 filing.

Tushar Patel, a director and 10% owner of Amneal Pharmaceuticals, sold 5,000,000 shares of Class A Common Stock on March 14, 2025.

Director J Kevin Buchi of Amneal Pharmaceuticals gifted 262,072 shares of Class A Common Stock to a trust on March 10, 2025.

Executive Vice President Andrew S. Boyer sold 125,000 shares of Amneal Pharmaceuticals, Inc. Class A Common Stock on March 5, 2025, at an average price of $8.89 per share.

Jason B. Daly, EVP and Chief Legal Officer of Amneal Pharmaceuticals, sold a total of 90,000 shares of Class A Common Stock in two transactions on March 5th and 6th, 2025.

Tasos Konidaris, Executive Vice President & CFO of Amneal Pharmaceuticals, sold 100,000 shares of Class A Common Stock on March 5, 2025, at an average price of $8.91 per share.

Director Alva Emily Peterson sold 80,000 shares of Amneal Pharmaceuticals (AMRX) on March 5, 2025, at an average price of $8.90 per share.

Jason Daly, EVP and Chief Legal Officer of Amneal Pharmaceuticals, reports acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Executive Vice President Andrew Boyer reports transactions involving Amneal Pharmaceuticals Class A Common Stock, including acquisitions and disposals related to vesting of restricted stock units.

Executive Vice President and CFO of Amneal Pharmaceuticals, Tasos Konidaris, reports acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Chirag Patel, President & Co-CEO of Amneal Pharmaceuticals, reports the vesting and settlement of performance-based and regular restricted stock units, along with associated tax withholding.

Co-CEO of Amneal Pharmaceuticals, Chintu Patel, reports acquisition and disposal of Class A Common Stock and performance-based restricted stock units.

Gautam Patel, a director at Amneal Pharmaceuticals, sold 80,000 shares of Class A Common Stock on March 3, 2025, at an average price of $8.9 per share.